With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin. 

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries. 

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV. 

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids. 

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain. 

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity. 

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal? 

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV. 

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations. 

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.

With countries worldwide slowly legalizing cannabis, research is finally growing and we’re constantly finding out more about the 120+ cannabinoids in the marijuana plant, namely CBDV, otherwise known as Cannabidivarin. 

People are looking beyond conventional THC or CBD and seeking out new cannabinoids like this one, and in this article, we will explain why CBDV is worth looking into. The laws have limited public access and therapeutic research on non-psychoactive cannabinoids. Fortunately, we’re discovering more and more cannabinoids that are non-psychoactive and still have the healing properties of cannabis.

So, what is CBDV?

Cannabidivarin (CBDV) is a Varin cannabinoid first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” in 1977, and identified for the first time in 1969 Vollner et al. CBDV is a homolog of CBD and is a non-psychoactive cannabinoid. As you can see below, The slight difference here is the propyl chain that CBDV carries. 

Like CBD, cannabidivarin has 7 double bond isomers and 30 stereoisomers. There is a side-chain shortened by two methylene bridges. The biggest difference between CBD and CBDV is their concentrations in the cannabis plant. You can find trace amounts of CBDV in high-quality full-spectrum and broad-spectrum extracts that help to produce the entourage effect.

Varin cannabinoids (technically called varinolic cannabinoids) are a subfamily of cannabinoids that feature three carbons on their alkyl side chains. The most well-known examples are THCV, CBDV, CBGV, and CBCV. There are also acid forms of THCVA, CBDVA, CBGVA, and CBCVA.

CBDV exists in very small quantities. Recently, several African landrace strains (which are genetically pure and unimpacted by experimentation) of Cannabis indica were found to have CBDV and the related THCV in concentrations closer to 4%. There are also plant breeders creating high CBDV and THCV strains of hemp and marijuana — but the current record still sits below 7% CBDV. 

What are the medicinal effects?

Epilepsy

Due to the rise in popularity of CBDV, researchers are trying to discover its medical benefits. In 2014, GW Pharmaceuticals finished a Phase 1 clinical trial of its CBDV test product (known as GWP42006). The clinical trial explored the use of CBDV as an anti-epileptic drug. The company continues to research CBDV heavily. You won’t feel a psychoactive ‘high’ from CBDV. Instead, you can expect it similar effects to CBD. The lack of a ‘high’ means we can use CBDV similarly, which is still being researched.

GW were set to enter Phase III trials in late 2019 but had to terminate the study because of the pandemic. They’re currently recruiting for a new trial, and the CEO Justin Gover made the following statement;

“CBDV represents an additional product pipeline opportunity as a next-generation epilepsy therapy.”

This study follows the completion of a Phase 1 trial in 66 healthy subjects in 2014. In this trial, CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. Most importantly, following this trial, There were no serious or severe adverse events, nor any withdrawals due to adverse events.

Rett Syndrome

As you may know, Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms with no cure available to date. A study was done on mice with CBDV being administered for 14 days. The study restored compromised general health status of the mice, the sociability, and the brain weight in RTT. While more studies are required, this shows great promise for the medical use of CBDV.

Autism

Some of the most interesting recent research into CBDV has been around the subject of autism. This condition, which affects more children and adults every year, is still being researched to find effective medications. The use of CBDV for autism has rapidly gained popularity over the last two years.

The study suggests that CBDV targets subcortical excitatory glutamate systems both in autistic and neurotypical adults. This study compared the effects of CBDV in neurodiverse patients and neurotypical patients. They noted a higher degree of difference in ASD patients with elevated glutamate. Very little benefit was reported on those with normal glutamate levels.

Some studies have even shown that people diagnosed with autism spectrum disorder (ASD) have below-average anandamide levels in the brain, one of the body’s endocannabinoids. 

Pain

In this study, patients underwent two successive treatment phases (4 weeks each) and were treated with CBDV. While the study wasn’t necessarily conclusive, it did explore the potential utility of CBDV for neuropathic pain. 

While CBDV research is increasing, so far there are no guarantees that cures or applications have been or will be found. The existing CBDV studies and research papers indicate grounds for medical optimism that previously may not have existed. With the growing interest in the industry, there’s endless potential. Fortunately, there should not be severe restrictions on CBDV, considering its lack of psycho-activity. 

CBDV and the endocannabinoid system:

CBDV interacts with the endocannabinoid system (ECS) the same way as CBD. However, it’s thought to have about 25% of CBD potency. CBDV does not stimulate the ECS as CBD and THC do; it has a modulating action instead. According to the British Pharmacological Society;

“CBDV and all the acids inhibited DAGLα.”

DAGLα is an enzyme responsible for the synthesis of the endocannabinoid 2-AG.

Is CBDV Legal? 

CBDV is legal in the United States, as long as it is produced from Hemp rather than marijuana. This is because CBDV derived from marijuana is illegal on a federal level and is considered a schedule 1 drug by the Drug Enforcement Agency (DEA). Some states have legalized marijuana for medicinal or recreational use. The states that have legalized marijuana have also legalized its derivatives, including CBDV. 

CBDV derived from hemp containing no more than 0.3 percent THC is considered legal on a federal level due to the 2018 Farm Bill. This Bill gave states the power to further regulate hemp products, which some states have by restricting any traces of THC. Although hemp-derived CBDV is difficult to find, it’s legal in all states as long as it abides by the state THC regulations. 

What is the difference between CBDV and CBD?

As previously mentioned, the molecular structures between CBD and CBDV are different, which impacts their chemical responses. Furthermore, CBDV can be used to develop THCV (tetrahydrocannabivarin) when it’s exposed to an acidic environment. CBD doesn’t have this same ability to transform into THC. When dealing with CBDV vs CBD, both cannabinoids share huge similarities that could be a massive hit in the medical industry because of the therapeutic effects offered. Above all, CBD and CBDV both interact with the endocannabinoid system, but CBDV binds with the cannabinoid receptors and CBD simply interacts or blocks the receptors.

Based on all the information provided, it’s clear why Cannabidivarin might be the next significant cannabinoid the world will witness, and we can only hope that research increases to increase the use of CBDV globally.

Sometimes the most minor of molecules are the ones with the greatest impact. Such appears to be the case with CBG—the “first” cannabinoid that develops in cannabis. This seemingly insignificant cannabinoid is actually responsible for the creation of CBD, THC, and other cannabinoids catching the attention of scientists and consumers the world over.

Usually found in concentrations of <1% in most hemp plants, it’s no wonder this compound hasn’t received as much attention as others. However, that is quickly changing as more information is being unveiled about this once-overshadowed cannabinoid.

Below, we’ll take a closer look at CBG and the role it plays in the production of other cannabinoids. We’ll also explore its unique effects on the body, and how it differs from other hemp-derived cannabinoids.

What is CBG?

CBG, or cannabigerol, is a phytocannabinoid. Unlike endocannabinoids, which are produced by the body, phytocannabinoids are sourced from plants like cannabis. CBG is what's known as a non-intoxicating cannabinoid—it doesn’t get you high.

CBG: a not-so-minor cannabinoid

By the time cannabis is harvested, dried, and processed, it usually contains only trace amounts of CBG (below 1%). Hence, it is generally labelled a “minor” cannabinoid.

However, CBG—or rather, its acidic form, CBGA—is actually the first cannabinoid acid to develop in the cannabis plant. As such, it is sometimes referred to as the “stem cell” of cannabis. It is found in its highest concentrations in flowering cannabis plants. The acidic form is simply CBG with an extra carboxyl group—the “A”.

As plants continue to grow, enzymes convert CBGA into either THCA (tetrahydrocannabinolic acid), CBDA (cannabidiolic acid), or CBCA (cannabichromenic acid).

Following harvest, plants are usually dried and processed. The heat or UV light used in these scenarios breaks down these acidic cannabinoids into their non-acidic counterparts, such as THC, CBD, and CBC. This phenomenon is known as decarboxylation—the removal of a carboxyl group.

Decarboxylation also produces many other cannabinoids (at least 100), all of which originally stem from CBGA.

Most of the cannabis strains on today’s market are bred to be high in THC and/or CBD; and the more THC or CBD present in a plant sample, the less CBG. Hence, strains usually contain only small amounts of CBG.

However, some breeders are experimenting with crossbreeding, genetic manipulation, and even unique harvesting patterns to create strains that contain higher levels of this cannabinoid.

Bedrocan BV Medical Cannabis in the Netherlands, for example, has began harvesting some of its plants earlier to create a final product with higher levels of CBG.

What are the effects of CBG?

As we mentioned earlier, CBG is a non-intoxicating cannabinoid. Therefore, it does not interact with the endocannabinoid system in a way that interrupts mental faculties. However, just like any other cannabinoid, CBG does interact with the endocannabinoid system in a variety of ways.

CBG has been shown to increase appetite in two rat-based studies conducted by researchers at the University of Reading (UK) in 2016 and 2017.

Some studies also suggest that CBG may inhibit the growth of some tumours, while others show it may have neuroprotective effects. A 2014 study published in the PLoS One medical journal also claims that some CBG-derived products could suppress the body’s immune response.

Dr Bonni Goldstein, a medical doctor specialising in medicinal cannabis, claims that CBG can inhibit GABA neurotransmission in the brain, as well as affect pain, inflammation, and more.

“When GABA [uptake] is inhibited, you actually have muscle relaxation and you have anti-anxiety effects, so it [CBG] appears to promote similar effects that CBD Oil has. It also appears to have antidepressant and some modest antifungal properties” said Goldstein in a video for WeedMaps.

In 2013, researchers from the Department of Pharmacy at the University of Naples Federico II (Italy) tested the effects of CBG on an experimental model of experimental Inflammatory Bowel Disease (IBD). The researchers found that CBG has potential anti-inflammatory and antioxidant properties (Inflammatory Bowel Disease).

Unfortunately, because CBG has been overshadowed by cannabinoids THC and CBD, not a lot of research has gone into fully understanding this cannabinoid and its effects. However, that is slowly changing as people begin to realise the potential and importance of this compound.

CBG vs CBD. What is the difference?

Despite originating from CBG Oils, CBD Oil is completely distinct from CBG in both chemical structure and concentration within cannabis plants.

Because it is only found in trace amounts in dried plant material, it is only recently that manufacturers have begun to focus more attention on optimising CBG levels in products like CBD oils, supplements, and salves. It’s clear that CBG is an essential cannabinoid, but it’s yet unclear exactly how to use it to our benefit.

CBG (cannabigerol) and CBD (cannabidiol) are two of the many chemical compounds present in cannabis which can be used as medication. While they share similarities, there are important differences between them.

The main difference between CBG vs CBD is how the chemicals interact with our brain's cannabinoid receptors.

The cannabis plant contains at least 85 cannabinoids. These are chemical compounds which have an effect on the body by bonding with cannabinoid receptors in the brain. The most widely recognized and well studied of these chemicals is tetrahydrocannabinol (THC). THC is famous for being the main psychoactive component of cannabis, producing the high that gives the plant its medical and recreational effects.

However, there are many other less famous cannabinoids which also produce a range of effects on the brain. Two compounds which we will be focusing on in this article are cannabidiol (both CBD) and cannabigerol (CBG). While both CBD and CBG can be isolated from the cannabis plant, the main difference between them lies in how they interact with cannabinoid receptors.

As a result of this difference in action on cannabinoid receptors, CBD and CBG produce different effects when isolated from each other and when combined together in a full spectrum cannabis extract or both CBD product.

CBG vs CBD: What is the difference in effects?

The primary difference between CBD and CBG comes from their unique interaction with cannabinoid receptors. Cannabinoid receptors are found all over the body and brain, and modulate pain, inflammation, stress responses, mood etc. The way these chemical compounds interact with our cells is what gives them both their therapeutic and psychoactive effects.

Cannabinoid receptors are made up of many subunits. To date, scientists have identified two subtypes that play the largest role in our experience of cannabinoids: CB1 and CB2.

CB1 is mostly found in the brain, but also present in some other parts of the body. It has been linked to memory formation, reward seeking behavior, motor coordination, pain sensation, and more. CB2 is primarily found in the immune system where it regulates inflammation.

CBG vs CBD: What Is The Difference In How They Interact With Cannabinoid Receptors?

A 2010 study published by a group of scientists from Italy took a detailed look at the structure-activity relationships of CBG, CBD and THC.

The study found that both CBD and CBG interact strongly multiple cannabinoid receptors including the serotonin 5HT1a receptor. However, they differ in how they interact with cannabinoid receptors, mainly with respect to their effects on the endocannabinoid system (the biological system responsible for processing cannabinoids).

For example, CBD has no effect at all on the CB1 receptor, while CBG does. This is because CBD lacks affinity for CB1 due to an extra carbon atom in its molecular structure.

There was also found to be more CBG binding sites than CB2 binding sites throughout many parts of the brain and body, indicating that it's able to affect many different processes via its interaction with cannabinoid receptors.

CBG vs CBD: What Are The Benefits Of Each?

There are many differences between the effects CBG vs CBD produce, which also affects their therapeutic benefits. However, both CBG and CBD have potential uses as medication.

Cannabidiol (CBD)

This cannabinoid is famous for its non-intoxicating nature. It's this quality which has made CBD useful in treating children and people who can't tolerate the 'high' associated with THC and other cannabis compounds.

Also, CBD has been found to be an effective anticonvulsant, effectively treating seizures and epilepsy. This has been demonstrated in both animal and human studies.

Another study found that CBD reduced psychotic symptoms in schizophrenia, such as delusions and hallucinations which are often difficult to treat. These promising results show that CBD could be a useful medication for people with psychosis resulting from conditions such as bipolar disorder and schizophrenia.

Cannabigerol (CBG)

While CBG has been found to be non-psychoactive it does appear to improve the effects of THC. This is because, like CBD, it can modulate and reduce the negative side effects such as anxiety and paranoia that THC causes in some people.

As a result of this 'boosting' effect on THC, CBG appears to increase the pain relieving qualities of THC. This could make CBG useful in strains of cannabis used for medical benefits and purposes.

With Covid-19 impacting us for the last two years, the world is rapidly searching for ways that we can effectively manage the virus, despite the variants that constantly pop up. Finally, it seems that research is progressing and it’s the cannabis industry at the forefront of the latest research advancements by researchers affiliated with Oregon State University. These researchers conducted a study that suggests that cannabis compounds prevent Infection by the Covid-19 Virus.

The COVID-19 pandemic includes at least 272 million cases worldwide, 5.3 million deaths, and over 600 000 new cases daily. While the rollout of vaccines is underway, the rapid spread of COVID-19 underscores the need for new treatments.

Background Information:

In January 2021, this study looked into the possibility that cannabis may offer some help for patients with COVID-19. The study looks at one of the primary biological events that occur in patients with severe acute respiratory distress cases from COVID-19, something called a “cytokine storm.”

C.Sativa, a type of cannabis, was found in a cytokine storm study to reduce multiple cytokines and pathways related to inflammation and fibrosis. Two of the cytokines that C.Sativa reduced were TNFa and IL-6, which are thought to be the main targets when trying to block a COVID-19 cytokine storm and acute respiratory distress syndrome.

In another study done in September of 2020 on mice, they found the following;

“Several reports demonstrated that cannabidiol (CBD), a phytocannabinoid produced by the cannabis plant, can block IL-6 in several models of inflammatory diseases.”

What do the studies say in 2022?

A report on the research, “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants,” was published online on January 10th, 2022 by the Journal of Natural Products.

COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Researchers have found that the viral spike protein of SARS-CoV-2 to the human cell surface receptor angiotensin converting enzyme-2 (ACE2) is a critical step during the infection of human cells. The researchers looked into the following possibility:

“Therefore, cell entry inhibitors could be used to prevent SARS-CoV-2 infection as well as to shorten the course of COVID-19 infections by preventing virus particles from infecting human cells.”

Researchers discovered that cannabinoids increase the cell’s response to several key proteins produced by the coronavirus genome, which is an effect that had not been discovered prior to the study. Researchers also looked at how the proteins from the genome operated in human kidney cells and healthy control cells, both with and without cannabinoids.

Cannabis and its effectiveness against new variants:

The spike protein is the same part of the virus targeted by Covid-19 vaccines and antibody therapies. In addition to the spike protein, SARS-CoV-2 has three more structural proteins as well as 16 nonstructural proteins and several compounds van Breemen characterized as “accessory” proteins, all of which are potential targets for drugs developed to prevent Covid-19.

The two compounds commonly found in hemp - called cannabigerolic acid, or CBGA, and cannabidiolic acid, or CBDA - were identified during a chemical screening effort as having potential to combat coronavirus. In the study led by Richard van Breemen, a researcher with Oregon State’s Global Hemp Innovation Center, they found that cannabinoids bound to spike proteins found on the virus and blocked a step the pathogen uses to infect people, stating that;

“Cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells”

This means that cell entry inhibitors, like the acids from hemp, could be used to prevent SARS-CoV-2 infection and also to shorten infections by preventing virus particles from infecting human cells. They bind to the spike proteins so those proteins can’t bind to the ACE2 enzyme, which is abundant on the outer membrane of endothelial cells in the lungs and other organs.

The study then goes on to state that the most important piece of evidence found was that CBGA and CBDA were equally as effective against the alpha and beta variants. The abstract ends off on a highly positive note, expressing that cannabinoids do in fact have the potential to prevent and likely treat infection by SARS-CoV-2.

What other benefits could cannabis pose for Covid-19?

‍

1. Anxiety
   The number of people reporting high levels of anxiety has sharply elevated during the coronavirus (COVID-19) pandemic. The factors most strongly associated with high anxiety during the pandemic include loneliness, marital status, sex, disability, whether someone feels safe at home or not and work being affected by the coronavirus (COVID-19) pandemic.
   
   There is understandable concern about the impact of the pandemic on people’s well-being. Fortunately, though, compounds within cannabis have shown impressive anxiety-reducing qualities, particularly CBD, which has been shown in studies to increase serotonin activity and lower cortisol levels.

Is Cannabis safe to consume for Covid-19 patients?

While most people consume cannabis by smoking it, it is not the only way to consume it. Companies like ourselves offer multiple variations of consumption like edibles, tinctures and more that have very low THC, yet still offer the same benefits.

After the last two years of uncertainty, illness and chaos due to the pandemic, it’s relieving to see that cannabis has shown a lot of potential in fighting against COVID-19 and could potentially offer new solutions to tackle the pandemic.

Where can you get CBDA and CBGA products from?

The team here at Black Tie CBD is relieved and grateful that we’re a part of an industry that is helping to better global health in such an impactful way. As a company, we've seen the value in CBDA products and we've just released our brand new CBDA isolate so you can keep safe too.

‍

Black Tie Afghani CBD Hash is made with BlueBerry Pie Kief and a small amount of CBD oil. The ingredients are hand-worked until The hashish becomes elastic and has a potent aromatic smell. The effects are almost narcotic providing a super-relaxed feeling. It's easy to use by adding a small amount to a joint or pipe. The effects take about 2-3 minutes to kick in so, please use caution.

TOTAL CBD: 41.96% !!!  ?????

It's going to be a big week for Black Tie CBD! The crew is headed to Portland tomorrow to welcome the winner of the Golden Ticket Raffle, and to begin our Harvest at the farms. We are planning to bring you a live stream or 2 on our YouTube, new videos, and a ton of new images of the crop. We had a small setback with our main Instagram being taken down without reason, but we will be back with an even better page. Keep up with us on our trip for a lot of exclusives and what we've had going on at the farms.

‍